Potential significance of individual dosimetry of radionuclide therapy (RLT) using [177Lu]Lu-DOTA-TATE or mixture of [177Lu/90Y]-DOTA-TATE in NET therapy

#4582

Introduction: RTL targeted somatostatin receptors is increasingly available. Individual dosimetry performed during RLT of NET may enable to achieve better results of therapy with maintaining its safety.

Aim(s): The DUONEN multicentre randomised clinical trial is designed to evaluate the benefit of individual dosimetry on the efficacy and safety of RLT with [177Lu]Lu-DOTA-TATE or a mixture of [177Lu] and [90Y]DOTA-TATE in NET patients.

Materials and methods: The dosimetry procedure was performed for 113 cycles of RLT in 40 patients, with the use of QDose software based on 4 SPECT/CT scans and 5 blood samples. The doses absorbed to the kidneys was estimated with the Voxel-S method, while to the red marrow on the IDAC2 model using the TAC curve for blood obtained from the measurements (self-dose) and the segmented organs from images (cross-dose). The overall limit (for 4 cycles of RLT) for absorbed dose for kidney is less than 23 Gy and less than 2 Gy for red bone marrow.

Conference:

Presenting Author: Opalińska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: RLT, DUONEN, GEP-NET, Tandem RLT, dosimetry,